Pentoxifylline: A New Drug for the Treatment of Intermittent Claudication; Mechanism of Action, Pharmacokinetics, Clinical Efficacy and Adverse Effects
- 12 November 1984
- journal article
- clinical trial
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 4 (6), 297-306
- https://doi.org/10.1002/j.1875-9114.1984.tb03380.x
Abstract
During the past decade, the effectiveness of peripheral vasodilator drugs in the treatment of chronic occlusive arterial disease has been questioned. Pentoxifylline is a hemorheologic agent with primary actions that include increasing erythrocyte flexibility, reducing blood viscosity and increasing microcirculatory flow and tissue perfusion. The result is improved supply of oxygen to ischemic muscles of the limbs. In several double-blind studies, pentoxifylline increased walking distance of patients with intermittent claudication in comparison to placebo or vasodilators. Like other methylxanthines, pentoxifylline is well absorbed in the gastrointestinal tract, almost completely metabolized in the body and excreted in the urine. The most significant difference in its pharmacokinetics is that, unlike other methylxanthines, it is bound to the erythrocytic membrane where it is initially metabolized. Although pentoxifylline has been shown to be effective in the treatment of intermittent claudication, additional research is needed to determine its use as adjunctive therapy in patients with concurrent coronary or cerebrovascular disease.Keywords
This publication has 19 references indexed in Scilit:
- Pharmacology of Pentoxifylline A Hemorheologic Agent for the Treatment of Intermittent ClaudicationAngiology, 1984
- ASSESSMENT OF PHARMACOLOGICAL AGENTS WITH A HEMORHEOLOGICAL ACTIONAnnals of the New York Academy of Sciences, 1983
- Placebo Controlled Double Blind Study with Pentoxifylline of Walking Performance in Patients with Intermittent ClaudicationAngiology, 1983
- Pentoxifylline efficacy in the treatment of intermittent claudication: Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patientsAmerican Heart Journal, 1982
- Beneficial hemorheologic therapy of chronic peripheral arterial disorders with pentoxifylline: Results of double-blind study versus vasodilator-nylidrinAmerican Heart Journal, 1982
- Cardiovascular effects of aminophylline and pentoxifylline on intact dogs and isolated dog atria.Japanese Heart Journal, 1982
- Vasodilator Drugs in Peripheral Vascular DiseaseNew England Journal of Medicine, 1979
- Influence of pentoxifylline on erythrocyte deformability in peripheral occlusive arterial diseaseCurrent Medical Research and Opinion, 1979
- Improvement of the Flow Properties of Blood: a New Therapeutical Approach in Occlusive Arterial DiseaseAngiology, 1976
- THE CASE AGAINST VASODILATOR DRUGS IN OCCLUSIVE VASCULAR DISEASE OF THE LEGSThe Lancet, 1959